FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer

AstraZeneca (AZN) announced that the FDA expanded the label of its blockbuster cancer drug Imfinzi for a fourth indication in lung cancer.The FDA approved Imfinzi in combination with platinum-based chemotherapy for treating adults with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) with no known EGFR mutations or ALK rearrangements. While the Imfinzi-chemotherapy combo will be administered before surgery, Imfinzi monotherapy will be given after surgery.This approval is based on data fr ...